Kunal Jobanputra/LinkedIn
Apr 29, 2025, 17:47
Kunal Jobanputra Shares NEJM Study on Nonoperative Management of dMMR Tumors
Kunal Jobanputra, Consultant Medical Oncologist at Saifee Hospital, shared on X:
“Nonoperative management of dMMR tumors NEJM
Phase 2 study: 6mo dostarlimab (PD-1 inhibitor) for stage I-III dMMR solid tumors. 117 patients, 2 cohorts (rectal/nonrectal). Endpoints: clinical complete response (CCR), recurrence-free survival.
Results: 82% (84/103) achieved CCR, 80% avoided surgery!
- Cohort 1 (rectal): 100% CCR.
- Cohort 2 (nonrectal): 65% CCR. 2-yr recurrence-free survival: 92%.
Prostate and gastroesophageal showed lower rate of CCR
ctDNA showing impressive correlation with response to treatment.”
See more insights by NEJM on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 17:58
May 29, 2025, 17:45
May 29, 2025, 17:39
May 29, 2025, 17:28